MarkKupersmithMD

PubMed

• 259 citations
  High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.
  Roy W. Beck, Jonathan D. Trobe, Pamela S. Moke, Robin L. Gal, Xing D
  Archives of Ophthalmology. 2003-07-01
• 690 citations
  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis
  Roy W. Beck, Patricia A. Cleary, Malcolm M. Anderson, John L. Keltner, William T. Shults
  The New England Journal of Medicine. 1992-02-27
• 57 citations
  Fellow Eye Abnormalities in Acute Unilateral Optic Neuritis: Experience of the Optic Neuritis Treatment Trial
  Roy W. Beck, Mark J. Kupersmith, Patricia A. Cleary, Barrett Katz
  Ophthalmology. 1993-05-01

Journal Articles

• The Role of Monoamines in Learning and Memory Consolidation.  
  Boshes B, Moody R, Kupersmith M, and Zeller A, International Journal of Neurology 10:172-177
• Aspergillus Oryzae Meningitis.  
  Gordon W, Holzman R, Senter H, Lara E, and Kupersmith M, JAMA 235:2122-2123
• Treatment of Parkinson's Disease with Bromocriptine.  
  Lieberman A, Kupersmith M, Estey E, et al, New Engl J Med 295:1400-1404
• Treatment of Parkinson's Disease with Lergotrile Mesylate.  
  Lieberman A, Estey E, Kupersmith M, et al, JAMA 238:2380-2382
• Hemorrhage and Infarction in Anticoagulated Patients with Prosthetic Heart Valves.  
  Lieberman A, Hass WK, Pinto R, Isom O, Kupersmith M, et al, Stroke 9:18-24
• Bromocriptine in Parkinson's Disease: Further Studies.  
  Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goodgold A, and Goldstein M, Neurology 29:363-369
• Lergotrile in Parkinson's Disease: Further Studies.  
  Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goodgold A, and Goldstein M, Neurology 29:267-272
• Visual Symptoms in Migraine and Their Treatment.  
  Kupersmith M and Hass W, Stroke 10:299-305
• Neuropathy with Susceptibility to Compression Aggravated by Herniated Disc: Early Pathological and Electro-diagnostic Studies.  
  Kupersmith M, Lieberman A, Spielholz N, Berczeller P, and Ransohoff J, Arch Neurology 36:645-647
• Bromocriptine Mesylate in Parkinson's Disease New York State.  
  Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M, Tantaro T, J Med 79:1689-1692
• Dementia in Parkinson Disease.  
  Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Goodgold A, Korein J, and Goldstein M, Ann Neurology 6:355-359
• Bromocriptine and Lergotrile: Comparative Efficacy in Parkinson Disease.  
  Lieberman A, Kupersmith M, Casson I, Durso R, Foo SH, Khayali M, and Tartaro T, Adv in Neurology 24:461-463
• Dementias of Huntington's and Parkinson Disease.  
  Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Korein J, and Goldstein M, Adv Neurology 23:273-280
• Pergolide Mesylate: A Potent Day-Long Inhibitor of Prolactin in Rhesus Monkeys and Patients with Parkinson's Disease.  
  Kleinberg D, Lieberman A, Todd J, Greising J, Neophytides A, Kupersmith M, J of Clinical Endocrinol and Metab 51:152-154
• The Effect of Decortication on the Basal Ganglia Gaba Receptor.  
  Kupersmith M,Goldstein M, Neuroscience Letters 17:335-337
• The Effect of Specific Brain Lesions on the High Affinity Binding of Gaba in the Substantia Nigra.  
  Kupersmith M, Lieberman A, and Goldstein M, Brain Res 194:536-539
• Long-term Efficacy of Bromocriptine in Parkinson's Disease.  
  Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M, Bear G, and Goldstein M, Neurology 30:518-523
• Evaluation of Parkinson's Disease.  
  Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, and Korein J, Adv in Biochemical Psychopharmacology 23:277-286
• Visual Disturbances in Von Hippel Lindau's Disease.  
  Kupersmith M and Berenstein A, Ann Ophthalmol 13:195-197
• Visual Evoked Potentials in Chiasmal Gliomas in Four Adults.  
  Kupersmith M, Shakin E, Siegel I, Carr R, Ransohoff J, and Flamm E, Arch Neurol 38:362-365
• Reduced Contrast Sensitivity in Compressive Lesions of the Anterior Visual Pathway.  
  Kupersmith M, Siegel I, and Carr R, Neurology 31:550-554
• Effect of L-Glutamine and Isoniazid on Torticollis and Segmental Dystonia.  
  Korein J, Lieberman A, Kupersmith M, and Levidown L, Ann Neurol 10:247-250
• Treatment of Advanced Parkinson's Disease with Pergolide.  
  Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Peck V, Kleinberg D, Neurology 31:675-682
• Lisuride in Parkinson's Disease: Efficacy of Lisuride Compared to Levadopa.  
  Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, and Kleinberg D, Neurology 31:961-965
• The Cardiac Effects of Pergolide: A Potent and Long-Acting Dopamine Agonist.  
  Leibowitz M, Lieberman A, Goldstein M, Neophytides A, Kupersmith M, and Mehl S, Clin Pharmacol and Therap 30:718-723
• Join now to see all

Books/Book Chapters

• The Clinical Impact of the Blood Brain Barrier and its Manipulation. 
  Chapter: The Blood Ocular Barriers 
  Kupersmith MJ, Shakib MEditors: Ed Neult.Plenum Medical Book Co
• Neurovascular Neuro-ophthalmology. 
  Kupersmith MJSpringer- Verlag, Heidelberg
• Neurological Therapeutics Principals and Practice. 
  Chapter: Cavernous sinus disorders 
  Kupersmith MJ, Lefton DRMartin Dunitz Publishers, london
• The Cavernous Sinus: A Comprehensive Text. 
  Chapter: Endovascular techniques in the treatment of cavernous sinus aneurysms 
  Page 155 - 176Niimi Y, Berenstein A, Kupersmith MJEditors: Eisenberg MB, Ossama AM.Lippincott Williams & Wilkins, Philadelphia
• Ocular Anesthesia. 
  Chapter: Neuro-ophthalmic and Neurological Complications of Ophthalmic Anesthesia 
  Page 151 - 168Kupersmith MJEditors: Greenbaum S.W.B. Saunders
• Duane's Foundations of Clinical Ophthalmology. Volume 2. 
  Chapter: Visual Evoked Potential 
  Kupersmith MJEditors: Tasman W, Jaeger EA.JB Lippincott, Philadelphia
• The Eye In Systemic Disease. 
  Chapter: Tobacco-Alcohol Amblyopia 
  Page 477 - 479Kupersmith MJEditors: Gold DH, Weingeist TA.
• Biomedical Foundations of Ophthalmology, Vol 2. 
  Chapter: Visual Evoked Potential 
  Kupersmith MJJB Lippincott Co
• New Methods of Sensory Visual Testing. 
  Chapter: Contrast Sensitivity Testing 
  Kupersmith MJ, Holopigian K, and Seiple WHEditors: Sadun A and Wall M.
• The Swept Display Technique: Separation of the X- and Y- Dominated Evoked Potentials. 
  Page 123 - 134Nelson JI, Kupersmith MJ, Seiple WH, Carr REEditors: Nodar, R. and Barber, C.Butterworth Publishers
• Evoked Potentials. 
  Chapter: Electrophysiological Evaluation of Retinal Dysfunction in Ophthalmology 
  Page 333 - 342Kupersmith M and Siegel IEditors: Cracco, R.Q. and Bodis-Wollner, I.Williams and Wilkins
• Current Ocular Therapy. 
  Chapter: Angiomatosis Retinae 
  Kupersmith MJEditors: Fraunfelder, F.T.W.B. Saunders
• Hospital Medicine. 
  Chapter: Identifying Horner's Syndrome 
  Page 38 - 39Kupersmith M and Ransohoff J
• Parkinson's Disease - Current Progress, Problems and Management. 
  Chapter: The Use of Two New Dopamine Agonists: Pergolide and Lisuride in Parkinson's Disease 
  Page 335 - 356Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Pact V, Walker R, Zasorin N, Goodgold A, and Goldstein MEditors: U.K. Rinne, M. Klinger, and G. Stamm.Elsevier/North Holland Biomedical Press
• Advance in Biochemical Psychopharmacology. 
  Chapter: Bromocriptine in Parkinson's Disease: Report on 106 Patients Treated for Up to 5 Years 
  Page 245 - 253Lieberman A, Kupersmith M, Neophytides A, Gopinathan G, Casson I, Durso R, Foo SH, Khayali M, Tartaro T, and Goldstein MRaven Press, New York
• Catecholamines Basic and Clinical Frontiers. 
  Chapter: Bromocriptine and Lergotrile in Parkinson Disease 
  Page 1584 - 1586Lieberman A, Estey E, Gopinathan G, Kupersmith M, and Goldstein MEditors: E. Usdin, J. Kopin, J Barchas.Pergamon Press, Oxford and N.Y
• Dopaminergic Ergot Derivatives and Motor Function. 
  Chapter: Modification of the "on-off" Effect with Bromocriptine and Lergotrile 
  Page 285 - 295Lieberman A, Kupersmith M, Gopinathan G, Estey E, and Goldstein MEditors: K. Fuxe, D. Caine.Pergamon Press, Oxford and N.Y
• Neuro-ophthalmology Enters the Nineties. 
  Chapter: Ocular Myasthenia: Diagnosis and Treatment 
  Page 178 - 182Kupersmith MJ, H, Frohman L, et alEditors: J. Lawton-Smith, R Katz.Dutton Press
• Join now to see all

Abstracts/Posters

• Association for Research in Vision and Ophthalmology.
  Sadun A, Kupersmith MJ, J Neuro-ophthalmol 2001;21:227-230, Annual Meeting
• The Role of Monoamines in the Consolidation of Memory.
  Boshes B, Zeller A, Arbit J, Blonsky ER, Dolkart MA, Stahl S, Kupersmith M, International Congress of Neurology, Barcelona, Spain
• Treatment of Parkinson's Disease with Bromocriptine.
  Lieberman A, Kupersmith M, Vogel B, Goodgold A, Goldstein M, American College of Clinical Pharmacology, Philadelphia, Pennsylvania
• Treatment of Parkinson's Disease with Lergotrile Mesylate.
  Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M, Neurology 27, American Academy of Neurology, Atlanta, Georgia
• Lergotrile in Parkinson's Disease: Further Studies.
  Lieberman A, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M, 28th Annual Meeting, American Academy of Neurology, Los Angeles, California
• Bromocriptine in Parkinson's Disease: Further Studies.
  Lieberman A, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M, 28th Annual Meeting, American Academy of Neurology, Los Angeles, California
• Modification of the "On-Off" Effect with Bromocriptine and Lergotrile.
  Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goldstein M, International Symposium on Dopaminergic Ergot Derivatives and Motor Function, Wenner-Gren Center, Stockholm, Sweden
• Bromocriptine and Lergotrile in Parkison's Disease.
  Lieberman A, Estey E, Gopinathan G, Kupersmith M, Goldstein M, Fourth International Catecholamine Symposium, Asilomar Conference Center, Pacific Grove, California
• The Dementias of Huntington's and Parkinson's Disease.
  Lieberman A, Dziatolowski M, Kupersmith M, Aleksic S, Serby M, Korein J, Goldstein M, Symposium on Huntington's Disease, San Diego, California
• Pergolide and Lisuride for Parkinson's Disease.
  Lieberman A, Leibowitz M, Neophytides A, Kupersmith M, Mehl S, Kleinberg D, Serby M, Goldstein M, Lancet 11:1129-1130
• Long-Term Efficacy of Bromocriptine in Parkinson's Disease.
  Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M, Goldstein M, 31st Annual Meeting, American Academy of Neurology. Chicago, Illinois
• Dementia in Parkinson's Disease.
  Dziatolowski M, Lieberman A, Kupersmith M, Serby M, Goodgold A, Korein J, Goldstein M, International Symposium Ergot Alkaloids, New York, N.Y
• The Efficacy of a Potent Dopamine Agonist, Lisuride, in Parkinson's Disease.
  Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Walker R, Zasorin N, Pact V, Goldstein M, 32nd Annual Meeting, American Academy of Neurology. New Orleans, Louisiana
• The Efficacy of a Potent Long-Acting Dopamine Agonist, Pergolide, in Parkinson's Disease.
  Lieberman A, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Walker R, Zasorin N, Goldstein M, 32nd Annual Meeting, American Academy of Neurology. New Orleans, Louisiana
• Dissociation of VEP and Subjective Acuity in Chiasmal Gliomas.
  Siegel IM, Kupersmith MJ, Association for Research in Vision and Ophthalmology, Orlando, Florida
• Lisuride in Parkinson Disease.
  Lieberman AN, Neophytides A, Leibowitz M, Kupersmith M, Walker R, Zasorin N, Kleinberg D, Goldstein M, 81st Annual Meeting, American Society for Clinical Pharmacology and Therapeutics. San Francisco, California
• Pergolide in Parkinson Disease.
  Lieberman A, Leibowitz M, Kupersmith M, Neophytides A, Pact V, Mehl S, Kleinberg D, Goldstein M, 81st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Francisco, California
• Visual Evoked Potentials in Optic Chiasm Gliomas.
  Kupersmith MJ, Shakin E, Siegel I, Carr R, Ransohoff J, 48th Meeting, American Association of Neurological Surgeons, New York, New York
• Twenty Four Hour Suppression of Prolactin by Pergolide Mesylate, A New Ergot Drug.
  Kleinberg DL, Lieberman A, Todd J, Meddick J, Neophytides A, Kupersmith M, The Endocrine Society, Washington, D.C
• Reduced Contrast Sensitivity in Compressive Lesions of the Anterior Visual Pathway.
  Kupersmith MJ, Siegel I, Carr R, American Academy of Ophthalmology
• Twenty Four Hour Prolactin Suppression and Pituitary Tumor Shrinkage by Pergolide.
  Kleinberg DL, Greising J, Ragavan V, Seltzer T, Kricheff I, Kupersmith M, Flamm E, The Endocrine Society, Cincinnati, Ohio
• Further Studies with Lisuride, a Potent Dopamine and Serotonin Agonist in Patients with Parkinson's Disease Who are No Longer Satisfactorily Responding to Levodopa.
  Lieberman A, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Kupersmith MJ, American Society for Clinical Pharmacology and Therapeutics, New Orleans, Louisiana
• Neurophysiological Investigation of the 20/20 Eye in Multiple Sclerosis.
  Nelson JI, Kupersmith MJ, Seiple W, Weiss P, Carr R, A.R.V.O
• Neuro-Ophthalmologic Abnormalities and Percutaneous Transvascular Treatment of Giant Aneurysms of the Cavernous Carotid Artery.
  Kupersmith MJ, Berenstein A, Flamm E, Ransohoff J, 34th Annual Meeting of the American Academy of Neurology, Sheraton Washington Hotel, Washington, D.C
• The Evaluation of Transvascular Therapy of Intracavernous Carotid Aneurysms and Carotid-Cavernous Sinus Fistulas.
  Kupersmith MJ, Berenstein A, Choi IS, Fourth Meeting of the International Society of Neuro-ophthalmology, Princess Hotel, Bermuda
• Join now to see all

Lectures

• Acute homonymous quadrantanopia and patent foramen ovale. 
  Frank Walsh Ann Arbor
• Immunotherapy of the optic neuritis and autoimmune optic neuritis. 
  UMD of New Jersey Immunologic Disorders of the Visual System, Bally's Grand Hotel, Atlantic City
• Neurologic and ocular manifestations of sarcoidosis. 
  UMD of New Jersey Immunologic Disorders of the Visual System, Bally's Grand Hotel, Atlantic City
• Visual Field Reading Center-Optic Neuritis Treatment Trial. 
  The Optic Neuritis Study Group: ARVO Annual Meeting, Sarasota, FL
• The optic neuritis treatment trial: five year neurologic follow-up results. 
  NANOS, Keystone, Colorado
• The optic neuritis treatment trial: five year visual function follow-up results. 
  NANOS, Keystone, Colorado
• Visual outcome in patients with giant cell arteritis after one year of therapy. 
  NANOS, Keystone, Colorado
• Long term experience with cavernous carotid aneurysms. 
  Working Group Interventional Neuroradiology, France
• NANOS visual loss from giant cell arteritis. 
• Giant Cell Arteritis 1998. 
  Pennsylvania Ophthalmological Association
• Color doppler assessment of orbital blood flow in giant cell arteritis. 
  2nd International Glaucoma Meeting, Jerusalem
• Aneurysms of the cavernous carotid artery. 
  Interventional Neuroradiology, Val D’Sere
• Divergence insufficiency. 
  American Academy Ophthalmology. New Orleans
• Diagnosis and management of divergence weakness in adults. 
• Pediatric Neuro-ophthalmology. 
  Mount Sinai Medical Center
• Visual Field Reading Center Optic Neuritis Treatment Trial. 
  ARVO Annual Meeting, Sarasota, Florida
• Neuro-ophthalmology Symposium. 
  Am Acad Ophthalmol, New Orleans
• Ocular myasthenia gravis: edrophonium testing and effects of prednisone on incidence of generalized disease at two years. 
  Utah
• Case report: see-saw nystagmus as the presenting sign in an adult male with mri confirmed agensesis fo the optic chiasm. 
  ARVO, Ft. Lauderdale, FL
• Magnims clinically isolated syndrome workshope. 
  National Hospital at Queens Square London
• 10 year follow up of ONTT study. 
  NANOS, Orlando
• Early Corticosteroid Therapy Is Indicated for Ocular Myasthenia Gravis: Pro. 
  AAO, Chicago
• Ocular Myasthenia Gravis Treatment Trial. 
  NY Academy of Medicine meeting, Chicago
• 15-year Neurologic outcome Optic Neuritis Treatment Trial patients. 
  Charcot Society, ACTRIM, Prague
• Rationalizing GCA Treatment and Preventing Vision Loss. 
  4th International Conference on Giant Cell Arteritis and Polymyalgia Rheumatica, NY, NY
• Join now to see all

Other

• Method and apparatus for visual evoked responses. 
  Jeremiah Nelson and Mark Kupersmith, Patent #4,676,611
• Physiological Interpretation of the VER. 
  Kupersmith MJ, Seiple WH, and Nelson JI, Highlights in Neuro-ophthalmology pp.103-114